Plain-English translation of NCT06942416 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination treatment for women whose cervical cancer has come back after initial treatment or has spread to a few new locations. The combination includes two newer medications called (which help your immune system fight cancer), plus standard chemotherapy drugs and radiation therapy. Researchers want to see if this combination approach works better than current options and helps more patients survive longer.
Cervical cancer that returns or spreads to a few sites is very difficult to treat, and current options don't work well for everyone. This study exists to see whether adding immune-boosting medications to chemotherapy and radiation can improve survival and quality of life for patients in this situation.
You likely qualify if…
You likely don't qualify if…
You would receive the combination medication by infusion, chemotherapy, and targeted radiation therapy on a schedule designed by your care team. You would have regular clinic visits for blood tests, imaging scans, and check-ups to monitor how well the treatment is working and to watch for side effects. You would also provide small samples (blood, tissue, and stool) to help researchers understand which patients benefit most from this treatment. The study aims to enroll 36 women and follows them closely throughout treatment and afterward.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China